Background Due to individual differences and lack of objective biomarkers, only 30-40%
patients with major depressive disorder (MDD) achieve remission after initial antidepressant …

Objective Major depression disorder (MDD) is a harmful disorder, and the pathological
mechanism remains unclear. The primary pharmacotherapy regimen for MDD is selective …

Background Neuroimaging studies have demonstrated disrupted brain functional networks
in major depression disorder (MDD); however, alterations to whole‐brain networks …

Objective For major depressive disorder (MDD), there has been a lack of neuroimaging
markers of efficacy of pharmacological treatment. In this study, we aimed to explore the …

Objective Predefining the most effective treatment for patients with depressive disorders
remains a problem. We will examine the differential brain regions of gray matter (GM) in …

Background Radiomics is an emerging image analysis framework that provides more details
than conventional methods. In present study, we aimed to identify structural radiomics …

Background Due to the biological heterogeneity, 60%–70% of patients with major
depressive disorder (MDD) do not respond to or achieve remission from first‐line …

Background The diagnosis of subclinical depression (SD) currently relies exclusively on
subjective clinical scores and structured interviews, which shares great similarities with …

There is a critical need to identify objective predictive markers of treatment response in
major depressive disorder (MDD), given the high levels of illness morbidity and the fact that …

Background In order to reduce unsuccessful treatment trials for depression, neuroimaging
and genetic information can be considered as biomarkers. Together with machine‐learning …